Europe Extracorporeal Membrane Oxygenation Machine Market

Europe Extracorporeal Membrane Oxygenation Machine Market Size

The size of the Europe extracorporeal membrane oxygenation machine market was valued at USD 79 million in 2025. This market is expected to grow at a CAGR of 4.39% from 2026 to 2034 and be worth USD 116.29 million by 2034 from USD 82.47 million in 2026.

The extracorporeal membrane oxygenation machine market refers to the specialized life support systems that temporarily assume cardiopulmonary function in patients with acute respiratory or cardiac failure by oxygenating blood and removing carbon dioxide outside the body. These machines, deployed primarily in intensive care units, integrate a blood pump, oxygenator, heat exchanger, and monitoring interface to sustain end-organ perfusion during critical illness. Europe has emerged as a pivotal region for ECMO adoption due to advanced critical care infrastructure, high prevalence of severe respiratory conditions, and coordinated regional response protocols. According to sources, the number of intensive care units in the European Union capable of providing Extracorporeal Membrane Oxygenation (ECMO) therapy is growing, with a notable increase in capabilities and training programs following the COVID-19 pandemic. Apart from these, as per the official data from Eurostat, the median age of the EU's population reached 44.7 years on January 1, 2024. The median age has been consistently increasing, rising by 5.4 years from 39.3 years in 2004 to 44.7 years in 2024, intensifying susceptibility to cardiopulmonary emergencies. According to the European Centre for Disease Prevention and Control (ECDC), seasonal respiratory viruses, including influenza and RSV, place a significant and often unpredictable strain on European healthcare systems, particularly intensive care unit capacity, during the winter months. These demographic, clinical, and systemic factors collectively define the operational and strategic landscape for ECMO machine deployment across Europe.

MARKET DRIVERS

Expansion of Designated ECMO Centers Under National Critical Care Networks

The systematic establishment of high-volume ECMO referral centers across the region is a primary driver of the Europe extracorporeal membrane oxygenation machine market. This is supported by national health strategies and clinical governance frameworks. According to various sources, the number of countries and centers contributing data to the Extracorporeal Life Support Organization (ELSO) registry has seen a significant increase over recent decades, indicating growing global use and data sharing in the field of ECMO. In addition, the use of ECMO in Germany has shown a significant overall increase, with a notable number of hospitals using the therapy, though a large proportion of patient runs are concentrated in a smaller number of high-volume centers. Similarly, France has implemented a structured system for ECMO care, which includes the designation of various regional hubs to manage patient needs and facilitate appropriate transfers. These centers require dedicated ECMO machines with integrated safety alarms, biocompatible circuits, and real-time monitoring, maintaining several units per facility. The European Union's cross-border healthcare framework supports patient mobility and cooperation between member states, which allows for access to specialized, high-acuity treatments like ECMO in neighboring countries when needed. This structured ecosystem not only increases machine utilization but also justifies capital investment through demonstrated clinical necessity and outcome tracking.

Rising Incidence of Severe Respiratory Failure in Aging Populations

The growing burden of acute and chronic respiratory failure among the region’s aging demographic is significantly elevating demand for ECMO as a bridge to recovery or transplantation, which propels the expansion of the Europe extracorporeal membrane oxygenation market. As per research, the European Union population is aging, with the share of people aged 65 or older continuing to increase and projected to rise significantly by 2040. This cohort faces heightened vulnerability to pneumonia, influenza, and postoperative complications, leading to refractory hypoxemia. The incidence of hospitalizations for acute respiratory distress syndrome (ARDS) generally increases with advancing age, with a majority of cases occurring in older adult patients. The age-adjusted incidence of ARDS varies by region, with different studies in Italy and Spain reporting a range of incidence rates. ECMO is increasingly considered for eligible elderly patients when conventional ventilation fails with Survival rates among patients receiving venovenous extracorporeal membrane oxygenation (VV ECMO) are significantly lower in older age groups compared to younger patients. The increasing longevity and prevalence of multiple chronic conditions are expanding the population requiring potential ECMO support. Consequently, hospitals are driven to maintain operational readiness by ensuring they have sufficient ECMO machines and skilled perfusionists on standby.

MARKET RESTRAINTS

High Cost and Limited Reimbursement for ECMO Procedures

The substantial financial burden of ECMO therapy remains a major restraint to the Europe extracorporeal membrane oxygenation machine market. This burden affects several European healthcare systems due to inconsistent reimbursement policies and high procedural costs. The cost associated with an ECMO run varies across Western Europe. Coverage for ECMO treatment differs by country; some nations offer full coverage through established health systems, while others provide only partial reimbursement or require exceptional approval. Funding for ECMO in the UK requires individual case-by-case requests for conditions other than specific types of influenza-related respiratory distress. A number of intensive care units in Eastern Europe do not have formal pathways established for ECMO funding. These financial barriers deter hospitals from investing in capital equipment and trained personnel, particularly in regions with constrained health expenditures, thereby limiting equitable access and suppressing market growth despite clinical need.

Shortage of Trained Personnel and Standardized Protocols

The effective deployment of ECMO machines is mainly hampered by a shortage of specialized clinicians and the absence of harmonized training standards across the region, which hinders the expansion of the Europe extracorporeal membrane oxygenation machine market. According to studies, many EU member states do not have mandatory certification programs for ECMO specialists. There is an identified deficit of perfusionists and ECMO coordinators in the workforce. Certain countries have fewer than five trained ECMO operators nationwide. Moreover, differences in cannulation techniques, anticoagulation protocols, and circuit management contribute to outcome disparities, with survival rates for ECMO patients varying depending on the resources available in different healthcare settings. The human capital shortage in ECMO care will continue unless standardized simulation training and international credentialing are implemented, which limits the technology's safe and widespread adoption.

MARKET OPPORTUNITIES

Integration of Portable and Next Generation ECMO Systems

The development of compact mobile and simplified ECMO platforms offers a potential opportunity to expand life support access beyond traditional tertiary centers, which is expected to be the growth boosters for the Europe extracorporeal membrane oxygenation machine market. Several new portable ECMO devices have recently received key approvals, facilitating their use in clinical settings. Companies are introducing systems that are designed to be lightweight, enhancing their portability. Initial programs in some regions have shown that using these smaller units can achieve results comparable to traditional systems. Funding initiatives have supported innovation directed toward making ECMO technology more widely available and easier to deploy. These advances promise to democratize access, shorten transfer times, and enable earlier intervention, potentially improving survival in rural and underserved regions while creating new demand for agile and user-friendly machine architectures across Europe.

Expansion of ECMO Use in Cardiac and Transplant Applications

The growing application of ECMO in acute cardiac support and as a bridge to heart or lung transplantation, beyond respiratory failure, is opening prospects for the expansion of the Europe extracorporeal membrane oxygenation machine market. The utilization of venovenous ECMO for managing severe cardiogenic shock has increased significantly in recent years, reflecting its growing role as a salvage intervention. Extracorporeal membrane oxygenation (ECMO) serves as an established method of temporary mechanical circulatory support for selected patients with irreversible cardiac failure who are awaiting a heart transplant or a long-term ventricular assist device. The use of ex vivo lung perfusion technology in lung transplantation is an evolving area of research aimed at improving graft quality and potentially reducing complications like primary graft dysfunction. Regulatory bodies have responded by updating guidelines. Recent guidance from health bodies like the UK's National Institute for Health and Care Excellence has provided updated recommendations for the use of ECMO in specific, life-threatening scenarios such as refractory cardiac arrest and massive pulmonary embolism. The increasing use of ECMO machines in surgical settings reflects evolving mechanical circulatory support protocols and a recovery in transplant volumes post-pandemic, making them indispensable in cardiothoracic pathways.

MARKET CHALLENGES

Prolonged Machine Downtime Due to Maintenance and Disposables Shortages

Operational continuity of ECMO machines is frequently disrupted by extended servicing intervals and intermittent shortages of proprietary disposables, creating critical care vulnerabilities, which obstruct the growth of the Europe extracorporeal membrane oxygenation machine market. According to a study, ECMO systems often require maintenance at regular intervals, which typically results in periods of downtime while components like pump heads are replaced. More critically, the just-in-time supply model for oxygenators, tubing sets, and sensors, often single-sourced, led to stockouts. Hospitals have experienced challenges in maintaining continuous operational capacity of ECMO equipment during high-demand periods due to occasional shortages of necessary supplies. A significant portion of essential ECMO supplies is sourced from single providers, which can impact supply chain resilience. Unlike ventilators, ECMO circuits cannot be sterilized and reused, increasing dependency on uninterrupted logistics. These fragilities expose systemic risks in high-stakes environments where machine availability directly correlates with patient survival, thereby challenging the resilience of Europe’s critical care infrastructure.

Ethical and Resource Allocation Dilemmas in High-Demand Scenarios

The intensification of ethical conflicts surrounding ECMO candidacy and resource rationing during peak demand periods poses a profound non-technical barrier to ultimately constrain the expansion of the Europe extracorporeal membrane oxygenation machine market. As per sources, most critical care centers in a specific region of the world put patient prioritization systems in place during a recent severe respiratory season. These decisions often exclude elderly individuals or those with comorbidities, despite potential for recovery, raising questions of equity and ageism. In addition, Official guidance encourages clear rules for allocating scarce medical equipment, but a standard approach has not yet been adopted across all areas. Differences in the availability of life-saving medical techniques between various types of healthcare facilities and regions can create the impression of unequal access. In the absence of standardized ethical guidelines and real-time capacity tracking, these dilemmas will persist, hindering the use of ECMO machines, negatively impacting clinician morale, and inviting public scrutiny. This, in turn, will limit the broader societal acceptance and scalability of ECMO as a life-sustaining intervention.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Modality Insights

The Veno-arterial (VA) ECMO segment dominated the Europe extracorporeal membrane oxygenation machine market and captured a 58.4% share in 2024. Its dual support of both cardiac and respiratory failure makes it indispensable in scenarios such as cardiogenic shock, post-cardiotomy collapse, and bridge-to-transplant protocols, which drives the dominance of the Veno-arterial (VA) ECMO segment. A majority of ECMO procedures in transplant centers use the VA configuration. The use of VA ECMO is becoming the standard approach in high-acuity cardiac intensive care units. VA ECMO is considered the appropriate approach for patients experiencing both respiratory and hemodynamic instability. The modality’s versatility across cardiac surgery, cardiology, and general ICU pathways ensures consistent demand for machines equipped with high-flow pumps and robust monitoring for arterial line pressure and differential hypoxia, which cements its position as the clinical cornerstone of ECMO therapy in Europe.

The Veno-venous (VV) ECMO segment is predicted to witness the highest CAGR of 12.3% from 2025 to 2033 due to the rising burden of severe acute respiratory distress syndrome linked to viral pandemics, seasonal surges, and chronic lung disease decompensation. During the winter of 2023–2024, European healthcare systems observed an increase in hospitalizations due to severe acute respiratory infections, including viral pneumonia, which contributed to higher demand for advanced life support. Veno-venous Extracorporeal Membrane Oxygenation (VV ECMO) continued to be used as a primary rescue therapy for patients experiencing refractory hypoxemia when conventional ventilation failed. Following previous viral surges, such as the 2022 RSV wave, several countries and regional health networks reviewed and adjusted their critical care capacities and protocols for deploying ECMO. Research and development efforts, sometimes supported by collaborative funding programs like Horizon Europe, are actively pursuing simplifications in ECMO technology and protocols to potentially expand its use to a wider range of critical care centers and reduce the need for highly specialized personnel like perfusionists in all scenarios. These developments, combined with growing recognition of VV ECMO’s role in lung protective ventilation strategies, are enabling earlier intervention and broader geographical deployment across Europe’s respiratory critical care landscape.

By Application Insights

The respiratory segment led the Europe extracorporeal membrane oxygenation machine market and occupied a share of 61.7% in 2024. The growth of the respiratory segment is because of the entrenched use of ECMO as a rescue therapy for severe acute respiratory failure unresponsive to mechanical ventilation. According to sources, ECMO use for respiratory indications is common across the EU. National health systems have institutionalized ECMO pathways for respiratory failure, with France’s Ministry of Health mandating that all regional ECMO hubs maintain dedicated VV circuits and trained respiratory therapists. A majority of patients requiring ECMO have a primary respiratory illness, and outcomes are improving due to established care practices. Moreover, Current guidelines support the use of ECMO for patients experiencing severe respiratory distress who do not respond to standard treatments. This clinical consensus, supported by outcome data and public health preparedness, ensures respiratory applications remain the principal driver of ECMO machine utilization across Europe.

The extracorporeal cardiopulmonary resuscitation (ECPR) segment is estimated to register the fastest CAGR of 14.8% from 2025 to 2033, owing to the integration of ECPR into refractory cardiac arrest protocols in urban academic medical centers. The implementation of Extracorporeal Cardiopulmonary Resuscitation (ECPR) in various urban emergency medical systems shows improved outcomes for patients with cardiac arrest. Survival rates for specific cardiac arrest scenarios appear higher with ECPR protocols compared to traditional resuscitation methods when initiated promptly. The availability of ECPR services is expanding geographically, with numerous medical centers establishing continuous, dedicated response teams. National medical frameworks are increasingly integrating ECPR capabilities as a standard of care within certain specialized hospital settings. Clinical practices are evolving, and major intensive care medicine organizations have updated their guidelines to support the use of ECPR for carefully selected patients. These evidence-based endorsements, combined with mobile ECMO teams and public alert systems, are transforming ECPR from an experimental rescue into a structured emergency life support modality, which is driving unprecedented demand for rapid deployment ECMO machines across Europe.

COUNTRY-LEVEL ANALYSIS

Germany Extracorporeal Membrane Oxygenation Machine Market Analysis

Germany was the top performer in the Europe extracorporeal membrane oxygenation machine market and accounted for a 24.6% share in 2024. Its robust critical care infrastructure and federal support for ECMO network development drive the dominance of the German market. Multiple certified centers are operational nationwide, serving both respiratory and cardiac emergencies. The country maintains a high density of intensive care unit beds, facilitating rapid ECMO initiation when required. Germany also hosts key manufacturing and R and D hubs for global medtech firms, which collaborate with university hospitals on next-generation machine trials. The Federal Joint Committee fully reimburses ECMO procedures under diagnosis-related group codes, reducing financial barriers. Besides, mandatory perfusionist training and national outcome registries ensure high-quality care. These systemic strengths, combining clinical excellence, regulatory support, and industrial innovation, position Germany as the undisputed leader in ECMO adoption and technological advancement across Europe.

France Extracorporeal Membrane Oxygenation Machine Market Analysis

France was the second largest player in the Europe extracorporeal membrane oxygenation machine market by occupying a 19.3% share in 2024. Its centralized ECMO hub model and strong transplant medicine ecosystem have contributed to the expansion of the French market. The nation maintains a well-established and organized national network for delivering ECMO services, ensuring consistent care delivery across different regions. Respiratory failure is the primary indication for ECMO use, while a notable portion of procedures serve as a crucial support bridge to transplantation. France is also a pioneer in mobile ECMO, with teams from Paris and Lyon routinely deploying to peripheral hospitals via high-speed rail. Full reimbursement through the national health insurance system and integration with organ procurement agencies ensure seamless transitions from ECMO to transplant. Moreover, French academic centers lead clinical trials on anticoagulation-free circuits and bio-coated oxygenators. This convergence of public health strategy, academic leadership, and procedural volume sustains France as a high-performance and high-equity ECMO market in Western Europe.

United Kingdom Extracorporeal Membrane Oxygenation Machine Market Analysis

The United Kingdom is a noteworthy player in the Europe extracorporeal membrane oxygenation machine market because of its national ECMO service and robust outcome monitoring through the Intensive Care National Audit and Research Centre. Coverage for adult extracorporeal membrane oxygenation (ECMO) across the nation is provided by six designated centers, with referral pathways integrated into alert systems for ambulances and hospitals. The UK maintains a high survival to discharge rate for respiratory cases treated with ECMO. Guidelines were recently updated to broaden ECMO indications, which now include severe RSV bronchiolitis in specific adult patient groups. Despite post-Brexit regulatory divergence, the UK maintains alignment with EU medical device standards, ensuring uninterrupted access to advanced machines. Investment in ECPR protocols has also accelerated, with London and Manchester establishing 24/7 rapid response teams. These evidence-based, centralized, and transparent practices reinforce the UK’s role as a benchmark for quality and accountability in European ECMO care.

Italy Extracorporeal Membrane Oxygenation Machine Market Analysis

Italy is growing steadily in the Europe extracorporeal membrane oxygenation machine market due to a high respiratory disease burden and growing ECMO adoption in northern regions. As per sources, Intensive care unit admissions for viral pneumonia increased during the winter season. A significant number of extracorporeal membrane oxygenation (ECMO) procedures were performed, often utilized for acute respiratory distress syndrome linked to common respiratory infections. Italy benefits from strong academic-medical collaboration with centers in Milan and Bologna participating in ELSO’s European registry and pioneering prone positioning during VV ECMO. However, access remains uneven, with southern regions relying on inter-hospital transfers due to limited local capacity. Funding was directed towards enhancing intensive care unit capabilities, including readiness for advanced life support procedures, in several hospitals. These investments aim to reduce geographical disparities and align Italy’s ECMO capabilities with its epidemiological needs, which positions the country for sustained growth in life support delivery.

Sweden Extracorporeal Membrane Oxygenation Machine Market Analysis

Sweden is predicted to expand notably in the Europe extracorporeal membrane oxygenation machine market during the forecast period, owing to its integrated Scandinavian ECMO network and leadership in ECPR implementation. Sweden’s universal healthcare system ensures equitable access, with all five university hospitals maintaining 24/7 ECMO teams supported by national protocols and centralized training at Karolinska Institute. Sweden also pioneers portable ECMO deployment with units installed in air ambulances for interfacility transfers across Nordic countries. The Swedish Agency for Health Technology Assessment regularly reviews cost-effectiveness, ensuring sustainable funding. This combination of clinical innovation, outcome transparency, and regional cooperation establishes Sweden as a high-efficiency model for ECMO delivery in Northern Europe.

COMPETITIVE LANDSCAPE

The Europe extracorporeal membrane oxygenation machine market features intense competition among established medtech leaders distinguished by technological reliability, clinical validation, and educational support. Getinge, Medtronic, and Xenios dominate through differentiated platforms ranging from high acuity intensive care systems to mobile emergency units, each aligned with specific European care pathways. Competition centers on biocompatibility, circuit simplicity, and integration with hospital monitoring networks rather than price due to the life-critical nature of the technology. Regulatory compliance under the EU Medical Device Regulation is non-negotiable, with companies investing heavily in post-market surveillance and cybersecurity for connected devices. Emerging players face high barriers, including the need for outcome registries, trained service teams, and partnerships with national ECMO networks. Differentiation increasingly hinges on data-driven insights, AI-enabled alerts, and the sustainability of disposable supply. As ECPR and decentralized ECMO expand, competition will intensify around the speed of deployment, ease of use, and interoperability with emergency medical systems across diverse European healthcare environments.

KEY MARKET PLAYERS

The leading companies operating in the Europe extracorporeal membrane oxygenation machine market include:

• Getinge Group
• Medtronic plc
• LivaNova PLC
• XENIOS AG
• Terumo Corporation
• MicroPort Scientific Corporation
• NIPRO Corporation
• OriGen Biomedical Inc.
• ALung Technologies Inc.
• EUROSETS S.r.l.

TOP PLAYERS IN THE MARKET

• Getinge AB is a cornerstone of the Europe extracorporeal membrane oxygenation machine market through its Rotaflow and CardioHelp systems, which are widely deployed across German, Scandinavian, and Benelux intensive care units. The company contributes globally by integrating biocompatible circuit design with real-time hemodynamic monitoring to enhance patient safety during prolonged ECMO runs. Recently, Getinge expanded its clinical support network across Southern Europe, launching specialized training academies in Milan and Madrid to certify perfusionists and intensivists on next-generation platform protocols. It also partnered with European university hospitals to collect real-world outcome data on anticoagulation management in elderly patients. These initiatives reinforce Getinge’s commitment to clinical excellence, technological reliability, and education-driven adoption in high acuity settings across Europe and worldwide.
• Medtronic plc plays a pivotal role in the European ECMO landscape through its Affinity and Quantum systems, which emphasize compact design and rapid deployment for both respiratory and cardiac applications. The company leverages its global cardiovascular expertise to support ECPR programs in urban academic centers across the UK, France, and the Netherlands. In recent developments, Medtronic upgraded its oxygenator portfolio with a new bioactive coating that reduces thrombogenicity, allowing for lower heparin dosing, a critical advantage in bleeding-prone patients. It also initiated a pan-European registry in collaboration with the European Society of Intensive Care Medicine to track long-term neurological outcomes post-ECPR. These actions demonstrate Medtronic’s strategic focus on biocompatibility innovation and evidence generation to strengthen its clinical relevance and operational footprint in Europe’s evolving life support ecosystem.
• Xenios AG, a subsidiary of Fresenius Medical Care, is a leading innovator in portable and simplified ECMO technology tailored for European critical care mobility needs. Its i-cor system enables rapid initiation and transport of patients between hospitals while maintaining circuit integrity. The company has significantly advanced decentralized ECMO access by deploying mobile units in air ambulances across Sweden and Germany. Recently, Xenios enhanced its digital dashboard with AI-driven alerts for oxygenator clotting and pump flow anomalies, reducing adverse events in non-specialist centers. It also expanded its disposable manufacturing capacity in Bad Homburg, Germany, to ensure supply chain resilience for oxygenators and cannulas. Through engineering agility and integration with Fresenius’ renal and critical care networks, Xenios strengthens Europe’s capacity for timely and safe extracorporeal life support beyond traditional tertiary hubs.

TOP STRATEGIES USED BY THE KEY MARKET PARTICIPANTS

Key players invest in compact and portable ECMO platforms to enable rapid deployment in emergency and transport settings across Europe. They develop biocompatible oxygenators and circuits that minimize anticoagulation requirements, improving safety in high bleeding risk patients. Companies establish regional training academies and simulation centers to address the shortage of certified ECMO specialists, particularly in Southern and Eastern Europe. Strategic collaborations with academic hospitals and professional societies generate real-world evidence on outcomes supporting guideline inclusion and reimbursement. Supply chain resilience is prioritized through local manufacturing of disposables and just-in-case inventory models to prevent critical shortages during viral surges.

MARKET SEGMENTATION

This Europe extracorporeal membrane oxygenation machine market research report is segmented and sub-segmented into the following categories.

By Modality

• Veno-Arterial (VA)
• Veno-Venous (VV)
• Arterio-Venous (AV)

By Application

• Respiratory
• Cardiac
• Extracorporeal Cardiopulmonary Resuscitation (ECPR)

By Country

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe